Penningtons Manches has advised NeRRe Therapeutics on its £23 million Series B funding round. The funding involved a syndicate of leading transatlantic life sciences investors led by new investor Fountain Healthcare Partners, and co-led by Forbion Capital Partners and OrbiMed. Existing investors Advent Life Sciences and Novo A/S also participated.
NeRRe is a clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity.
Penningtons Manches has advised NeRRe since its Series A funding in 2012. This deal showcases our strength in advising companies on growth capital deals, and our work in the life sciences sector more generally. The team was led by corporate partner Justin Starling, with support from corporate associates Elizabeth Yell and Chris Voelker.